NUVB Valuation
Nuvation Bio Inc
$
2.460
- Overview
- Forecast
- Valuation
NUVB Relative Valuation
NUVB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NUVB is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.65
P/B
Median3y
1.11
Median5y
-4.18
-17.09
FCF Yield
Median3y
-17.27
Median5y
-13.62
Competitors Valuation Multiple
The average P/S ratio for NUVB's competitors is 115.38, providing a benchmark for relative valuation. Nuvation Bio Inc Corp (NUVB) exhibits a P/S ratio of 53.48, which is -53.65% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
GRVY
Gravity Co Ltd
60.150
USD
+0.86%
DDD
3D Systems Corp
2.010
USD
+6.35%
AHG
Akso Health Group
1.361
USD
-2.79%
DCGO
DocGo Inc
2.310
USD
+5.00%
ORGO
Organogenesis Holdings Inc
5.280
USD
+6.45%
PRTC
PureTech Health PLC
17.550
USD
-0.62%
TBPH
Theravance Biopharma Inc
10.370
USD
-0.19%
LSAK
Lesaka Technologies Inc
4.490
USD
-3.44%
MEI
Methode Electronics Inc
6.680
USD
+4.70%
METC
Ramaco Resources Inc
10.000
USD
+0.50%
FAQ
Is Nuvation Bio Inc (NUVB) currently overvalued or undervalued?
Nuvation Bio Inc (NUVB) is now in the Fair zone, suggesting that its current forward PS ratio of 53.48 is considered Fairly compared with the five-year average of 46.46. The fair price of Nuvation Bio Inc (NUVB) is between to according to relative valuation methord.
What is Nuvation Bio Inc (NUVB) fair value?
How does NUVB's valuation metrics compare to the industry average?
What is the current P/B ratio for Nuvation Bio Inc (NUVB) as of May 03 2025?
What is the current FCF Yield for Nuvation Bio Inc (NUVB) as of May 03 2025?
What is the current Forward P/E ratio for Nuvation Bio Inc (NUVB) as of May 03 2025?